MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on November 2, 2004; DOI: 10.1124/mol.104.004721


0026-895X/05/6702-375-382$20.00
Mol Pharmacol 67:375-382, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.004721v1
67/2/375    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dinh, D. T.
Right arrow Articles by Thomas, W. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dinh, D. T.
Right arrow Articles by Thomas, W. G.
ORIGINAL ARTICLE

Helix I of {beta}-Arrestin Is Involved in Postendocytic Trafficking but Is Not Required for Membrane Translocation, Receptor Binding, and Internalization

Diem T. Dinh, Hongwei Qian, Ruth Seeber, Esther Lim, Kevin Pfleger, Karin A. Eidne, and Walter G. Thomas

Baker Heart Research Institute, Melbourne, Australia (D.T.D., H.Q., W.G.T.); and Western Australian Institute for Medical Research, Centre for Medical Research, Sir Charles Gairdner Hospital, University of Western Australia, Perth, Australia (R.S., E.L., K.P., K.A.E.)

Abstract

{beta}-arrestins bind to phosphorylated, seven-transmembrane-spanning, G protein-coupled receptors (GPCRs), including the type 1 angiotensin II receptor (AT1R), to promote receptor desensitization and internalization. The AT1 R is a class B GPCR that recruits both {beta}-arrestin1 and {beta}-arrestin2, forming stable complexes that cotraffic to deep-core endocytic vesicles. {beta}-Arrestins contain one amphipathic and potentially amphitropic (membrane-targeting) {alpha}-helix (helix I) that may promote translocation to the membrane or influence receptor internalization or trafficking. Here, we investigated the trafficking and function of {beta}-arrestin1 and {beta}-arrestin2 mutants bearing substitutions in both the hydrophobic and positively charged faces of helix I. The level of expression of these mutants and their cytoplasmic localization (in the absence of receptor activation) was similar to wild-type {beta}-arrestins. After angiotensin II stimulation, both wild-type and {beta}-arrestin mutants translocated to the cell membrane, although recruitment was weaker for mutants of the hydrophobic face of helix I. For all {beta}-arrestin mutants, the formation of deep-core vesicles was less observed compared with wild-type {beta}-arrestins. Furthermore, helix I conjugated to green fluorescent protein is not membrane-localized, suggesting that helix I, in isolation, is not amphitropic. Bioluminescence resonance energy transfer analysis revealed that both wild-type and {beta}-arrestin mutants retained a capacity to interact with the AT1R, although the interaction with the mutants was less stable. Finally, wild-type and mutant {beta}-arrestins fully supported receptor internalization in human embryonic kidney cells and mouse embryonic fibroblasts deficient in {beta}-arrestin1 and -2. Thus, helix I is implicated in postmembrane trafficking but is not strongly amphitropic.


Received for publication July 9, 2004.

Accepted for publication October 29, 2004.

Address correspondence to: Dr. Walter G. Thomas, Baker Heart Research Institute, P.O. Box 6492, St. Kilda Road Central, Melbourne 8008, Australia. E-mail: walter.thomas{at}baker.edu.au




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
S. M. Hanson and V. V. Gurevich
The Differential Engagement of Arrestin Surface Charges by the Various Functional Forms of the Receptor
J. Biol. Chem., February 10, 2006; 281(6): 3458 - 3462.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics